Screening for colorectal cancer: Alternative faecal occult blood tests

European Journal of Gastroenterology and Hepatology

Volumn 10, Issue 3, 1998, Pages 205-212

  Young, Graeme P ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Colorectal cancer screening; Faecal occult blood tests

Indexed keywords

GUAIAC; PEROXIDASE;

CANCER SCREENING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMMUNOCHEMISTRY; OCCULT BLOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0031900932     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199803000-00003     Document Type: Review

References (33)

1. Lieberman D, Sleisenger MH. Is it time to recommend screening for colorectal cancer? Lancet 1996; 348:1463-1464.
2. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult Wood screening for colorectal cancer. Lancet 1996; 348:1472-1477. Biennial screening in Nottingham with Hemoccult decreases mortality on an intention-to-screen basis by 15% (by 40% in compliers).
3. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sandergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-1471. Biennial screening in Funen, Denmark with Hemoccult decreases mortality on an intention-to-screen basis by 19% (by 40% in compliers).
4. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-1371. Annual screening with rehydrated Hemoccult decreases mortality on an intention-to-screen basis by 33% but with a high positivity rate and subsequent colonoscopy in over 30% of screenees at some time during the 13 year follow-up period.
5. Hardcastle JD, Bennett DH, Whynes DK. Mass screening: European/ UK perspective. In: Prevention and early detection of colorectal cancer. Young GP, Rozen P, Levin B (editors). London: Saunders; 1996. pp. 275-288.
6. St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, et al.: Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993; 104:1661-1668. Example of preliminary comparison of different occult blood tests prior to considering use in screenees.
7. Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for the first 107,349 subjects. Lancet 1989; 1:1160-1164.
8. Kronborg O, Fenger C, Olsen J, Bech K, Sondergaard O. Repeated screening for colorectal cancer with faecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989; 24:599-606.
9. Young GP, St John DJB. Selecting an occult blood test for use as a screening tool for large bowel cancer. Front Gastrointest Res 1991; 18:135-156.
10. Young GP, St John DJB, Rose IS, Blake D. Haem in the gut, II. Faecal excretion of haem and haem-derived porphyrins and their detection. J Gastroenterol Hepatol 1990; 5:194-203.
11. Young GP, Macrae FA, St John DJB. Clinical methods for early detection: Basis, use and evaluation. In: Prevention and early detection of colorectal cancer. Young GP, Rozen P, Levin B (editors). London: Saunders; 1996. pp. 241-270. Extensive review of screening tests, biology of bleeding and usage of faecal occult blood tests.
12. Young GP, St John DJB. Faecal occult blood tests: choice, usage and clinical applications. Clin Biochem Rev 1992; 13:161-167. Review of biochemical basis of faecal occult blood tests.
13. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown; 1985:76-126.
14. St John DJB, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA. Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med 1992; 117:376-382.
15. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Ellefson M, Owen RA. HemoQuant, a new quantitative assay for faecal haemoglobin. Comparison with Hemoccult. Ann Intern Med 1984; 101:297-302.
16. Macrae FA, St John DJB. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82:891-898.
17. Rose IS, Young GP, St John DJB, et al. Effect of ingestion of hemoproteins on faecal excretion of haems and porphyrins. Clin Chem 1989; 35:2290-2296.
18. St John DJB, Young GP. Is there a need to restrict diet in occult blood screening for colorectal cancer? Gastroenterology 1992; 102:A402.
19. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88:820-387.
20. Lynch NM, McHutchison JG, Young GP, Deacon M, St John DJB, Barraclough D. Gastrointestinal blood loss from a new buffered aspirin (Ostoprin): measurement by radiochromium and HemoQuant™ techniques. Aust NZ J Med 1989; 19:89-96.
21. Saito H, Yoshida Y. Mass screening: Japanese perspective. In: Prevention and early detection of colorectal cancer. Young GP, Rozen P, Levin B (editors). London: Saunders; 1996. pp. 301-312.
22. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. Effect of faecal occult blood testing on mortality from colorectal cancer. Ann Intern Med 1993; 118:1-6.
23. Weller D, Thomas D, Hiller J, Woodward A, Edwards J. Screening for colorectal cancer using an immunochemical test for faecal occult blood: results of the first 2 years of a South Australian programme. Aust N Z J Surg 1994; 64:464-469
24. Fujita M. Colon cancer screening by immunochemical RPHA occult blood test. In: Faecal occult blood tests. Young GP, Saito H (editors). San Jose, CA: SmithKline Diagnostics; 1992. pp. 82-89.
25. Iwase T. The evaluation of an immunochemical occult blood test by reversed passive haemagglutination compared with Hemoccult II in screening for colorectal cancer. In: Faecal occult blood tests. Young GP, Saito H (editors). San Jose, CA. SmithKline Diagnostics; 1992. pp. 90-95.
26. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez Bigas M: Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol 1994; 3:27-36.
27. Frommer D. Comparison of bowel cancer screening costs using immunological and Hemoccult techniques for detecting faecal occult blood. In: Faecal occult blood tests. Young GP, Saito H (editors). San Jose, CA: SmithKline Diagnostics; 1992. pp. 46-49.
28. Castaglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P, et al. Immunochemical vs guaiac faecal occult blood tests in a population-based screeningprogramme for colorectal cancer. Br J Cancer 1996; 74: 141-144.
29. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of faecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155-159. Direct comparison of different tests in a large screening population in California with follow-up over at least 2 years to confirm sensitivity and specificity. Found a surprisingly high positivity rate with HemoccultSENSA.
30. Levin B, Hess K, Johnson C, Gray P, Mailer A, Martin S. Screening for colorectal cancer: a comparison of 3 faecal occult blood tests. Arch Intern Med 1997; 157:970-976. Direct comparison of Hemoccult II, HemoccultSENSA and rehydrated Hemoccult, in a large screening population in Texas. Found an acceptable positivity rate with HemoccultSENSA.
31. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81:448-451.
32. Petty MT. Deacon MC, Alexeyeff MA, St John DJB, Young GP. Evaluation of the readability of Hemoccult and HemoccultSENSA test for faecal occult blood in the hospital ward environment. Med J Aust 1992; 156:420-423.
33. Feinberg EJ, Steinberg WM, Banks BL, Henry JP. How long to abstain from eating red meat before faecal occult blood tests. Ann Intern Med 1990; 113: 403-404.